The Company was incorporated on 02.11.1994. The certificate of commencement of business was received by the company on 10.03.1995.The IPO of the company was 30.01.1996 with 5100800 shares of Rs10/-each. The promoters were earlier in manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The company then discontinued its business activities for few years due to various reasons. The company also plans to extend its activity in formulation of Tablets, Capsules, Ointments, & Injectable.

Our Business

The active pharmaceutical ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax’s pharmaceutical operations. Starting from our journey as a bulk drug manufacturer and speciality chemicals in 1994.

We leverage our scientific expertise and strong manufacturing capabilities for in-house Production and to serve the needs of our customers.

Our Offerings

We use Quality by Design techniques to produce complex molecules enabling customers to create successful formulations. Our manufacturing units run in accordance with Current Good Manufacturing Practices (cGMP).

Our supply chain is resilient, supported by strategic sourcing partnerships. We provide excellent customer service through a dedicated team of quality, regulatory, and commercial experts.

We utilize flow chemistry for hazardous and cryogenic reactions. The driver to adopt this is a move towards sustainable manufacturing with improved green metrics, lower operating costs, and minimal manual operations. We are also in the process of commissioning a modular plant for an intermediate to API process encompassing multiple reactions and unit operations.

For several pharmaceutical companies, we are a partner of choice for APIs and will continue to maintain our leadership through new product offerings, cost competencies, and high service standards.